

Alerts and Recalls

Generic Name (Trade Name—Company)

November 26, 2018

Multiple generic names

(Multiple trade names—Mylan)

Mylan recalls valsartan products found to contain NDEA

Uses/Notes

FDA is [alerting](#) patients and health professionals to Mylan's voluntary [recall](#) of 15 lots of valsartan-containing products that contain *N*-nitrosodiethylamine (NDEA).

Not all Mylan valsartan-containing products distributed in the United States are being recalled. Mylan is recalling only those lots of valsartan-containing products that tested positive for NDEA above the acceptable level. The agency continues to investigate and test all angiotensin II receptor blockers (ARBs) for the presence of NDEA and *N*-nitrosodimethylamine (NDMA) and is taking swift action when it identifies these impurities that are above acceptable levels.

FDA has updated lists of [valsartan products under recall](#) and [valsartan products not under recall](#).

In addition, FDA reminds patients taking this medication or any recalled ARB to continue taking their current medicine until their pharmacist provides a replacement or their doctor provides an alternative treatment option. It also is important to know not all ARBs contain NDMA or NDEA, so pharmacists may be able to provide a refill of medication not affected by the recall, or doctors may prescribe a different medication that treats the same condition.

FDA has also posted [questions and answers](#) to assist health professionals and patients.

Source URL:

<http://aphanet.org/alerts-and-recalls/mylan-recalls-valsartan-products-found-contain-ndea>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.